These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19326477)

  • 1. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
    Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
    Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
    Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
    Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
    Assié MB; Bardin L; Auclair A; Consul-Denjean N; Sautel F; Depoortère R; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):241-50. PubMed ID: 17453175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
    Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
    Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
    Depoortère R; Auclair AL; Bardin L; Bruins Slot L; Kleven MS; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):266-77. PubMed ID: 17375085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
    Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
    Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
    Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
    Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
    Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
    J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission.
    Tanahashi S; Yamamura S; Nakagawa M; Motomura E; Okada M
    Neuropharmacology; 2012 Feb; 62(2):765-74. PubMed ID: 21925189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
    Terranova JP; Chabot C; Barnouin MC; Perrault G; Depoortere R; Griebel G; Scatton B
    Psychopharmacology (Berl); 2005 Aug; 181(1):134-44. PubMed ID: 15830220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.
    Boulay D; Depoortère R; Louis C; Perrault G; Griebel G; Soubrié P
    Neuropharmacology; 2004 Jun; 46(8):1121-9. PubMed ID: 15111019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT
    De Gregorio D; Posa L; Ochoa-Sanchez R; McLaughlin R; Maione S; Comai S; Gobbi G
    Pharmacol Res; 2016 Nov; 113(Pt A):81-91. PubMed ID: 27544651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.